Ensifentrine has attracted attention in respiratory drug development because it combines inhibition of two phosphodiesterase enzymes, PDE3 and PDE4, in a single molecule. Developed by Verona Pharma, it is the active ingredient in Ohtuvayre, an inhaled maintenance treatment for adults with chronic obstructive pulmonary disease (COPD).
The product’s commercial growth has also brought ensifentrine into focus. In October 2025, Merck & Co., known as MSD outside the United States and Canada, completed its approximately $10 billion acquisition of Verona Pharma. For pharmaceutical manufacturers, the product’s development offers insight into both the market potential and the formulation requirements of an innovative respiratory API.
What Is Ensifentrine?
Ensifentrine is a small-molecule, selective dual inhibitor of PDE3 and PDE4. The US Food and Drug Administration approved Ohtuvayre on June 26, 2024, for the maintenance treatment of COPD in adults.
The two targets contribute different pharmacological effects: PDE3 inhibition is associated with bronchodilation, while PDE4 inhibition contributes to non-steroidal anti-inflammatory activity. Ohtuvayre is administered as an inhalation suspension using a jet nebulizer. It is a maintenance medicine and is not intended to relieve acute bronchospasm.
Ensifentrine belongs to the broader field of respiratory system APIs, which includes active ingredients with different therapeutic applications, pharmacological targets and formulation requirements.
Ensifentrine Sales: How Did Ohtuvayre Perform in 2025?
Ohtuvayre’s commercial launch began in the United States in August 2024. Ligand Pharmaceuticals, which receives royalties on the product, estimated Ohtuvayre’s 2025 product revenue at approximately $488 million, compared with approximately $42 million in 2024. The 2025 figure is an estimate of product revenue, rather than a complete country-by-country sales breakdown.
Reported sales during 2025 show the pace of the launch:
| Reporting Period | Ohtuvayre Sales | Reporting Company |
|---|---|---|
| Q1 2025 | $71.3 million | Verona Pharma |
| Q2 2025 | $102.9 million | Verona Pharma |
| Q3 2025 | Approximately $136 million | Verona Pharma, as reported by Ligand |
| After October 7, 2025 | $178 million | Merck |
Merck’s $178 million figure covers sales recorded after its acquisition closed, rather than the entire fourth quarter or full year. The quarterly figures and Merck’s post-acquisition figure should therefore be read alongside their reporting periods.
Which Countries Are Important to the Ensifentrine Market?
The United States was the established commercial market driving Ohtuvayre’s 2025 sales. Public disclosures do not provide sufficient country-level figures to identify and rank five countries by actual 2025 sales. The following list therefore separates the confirmed US market from other countries that may be relevant to future development.
| Country | Market Context |
|---|---|
| United States | The principal commercial market in 2025. Ohtuvayre received FDA approval in 2024 and was launched there in August of that year. |
| China | A potential growth market under Nuance Pharma’s Greater China licensing agreement. Ohtuvayre was approved in Macau in 2025; the mainland China application was accepted for review in January 2026. |
| United Kingdom | A potential market where Verona submitted a marketing authorization application in June 2025. Future sales depend on regulatory and commercial progress. |
| Germany | A potential European market. Verona submitted an EU marketing authorization application in July 2025; an application does not establish approval or commercial sales. |
| Japan | A potential market to monitor, but the available disclosures do not support a 2025 Ohtuvayre sales ranking or a claim that it was an established commercial market. |
These countries should not be interpreted as a verified top-five sales ranking. Regulatory status and commercial availability should be checked in each target market when evaluating future opportunities.
Could Ensifentrine Become a Blockbuster Drug?
A blockbuster drug generally refers to a product generating more than $1 billion in annual sales. Ohtuvayre has the potential to reach that level, although it had not yet done so based on the 2025 estimate.
In a 2025 investor presentation, Ligand cited an analyst-consensus estimate of approximately $3.5 billion in peak annual sales. This is a forecast, not a reported result or a guarantee of future performance.
More recent results indicate continued commercial activity: Merck reported Ohtuvayre sales of $131 million in Q1 2026 and $204 million in Q2 2026. Merck noted that the second-quarter result benefited from the timing of specialty pharmacy purchases, which it expected to unwind in the following quarter. These figures support continued interest in the product but should not be treated as a simple full-year forecast.
Future sales will depend on factors such as prescription growth, patient access, reimbursement, competition and regulatory progress outside the United States. Potential development in additional indications or combinations could also affect long-term demand, but those opportunities require further clinical and regulatory evaluation.
How Does Ensifentrine Work?
Phosphodiesterases regulate cyclic nucleotides, including cyclic adenosine monophosphate (cAMP), which is involved in airway smooth muscle function and inflammatory cell activity. By inhibiting PDE3 and PDE4, ensifentrine influences signaling associated with airway relaxation and the modulation of inflammatory responses.
| Mechanism | Pharmacological Role | Relevance to COPD Treatment |
|---|---|---|
| PDE3 inhibition | Supports airway smooth muscle relaxation | Associated with bronchodilator activity |
| PDE4 inhibition | Modulates signaling in inflammatory cells | Contributes to non-steroidal anti-inflammatory activity |
| Dual PDE3/4 inhibition | Combines both mechanisms in one molecule | Provides a distinct approach to COPD maintenance treatment |
The combination provides a scientific rationale for the product, but clinical benefit and safety must be assessed through studies of the finished medicine.
How Is Ensifentrine Positioned Against Other COPD Treatments?
Ensifentrine’s main distinction is its dual PDE3/PDE4 mechanism. Other established COPD medicines act through different targets:
Beta-2 agonists and muscarinic antagonists primarily provide bronchodilation through different receptor pathways. For example, Salbutamol API is used in short-acting bronchodilator formulations.
Selective PDE4 inhibitors target PDE4 rather than combining PDE3 and PDE4 inhibition.
Inhaled corticosteroids address inflammation through a steroid-based mechanism and are used in selected COPD treatment regimens.
Ohtuvayre is positioned as a nebulized maintenance option with bronchodilator and non-steroidal anti-inflammatory effects in one molecule. Nebulized delivery also offers an administration approach that does not require high inspiratory flow or complex hand-breath coordination. However, device use, treatment time and individual patient needs remain relevant considerations.
These differences do not establish that ensifentrine is superior to every competing treatment. Treatment selection depends on clinical evidence, patient characteristics, access and applicable guidance.
The wider range of pharmaceutical raw materials used in respiratory medicine also includes ingredients with roles distinct from bronchodilation, such as mucolytic agents.
Ensifentrine and Inhalation Formulation Development
The approved product demonstrates why respiratory API development must be considered together with the finished dosage form and delivery device. Ohtuvayre is an aqueous inhalation suspension administered by jet nebulizer.
For a suspension-based product, developers may need to evaluate particle characteristics, dispersion, redispersibility, physical stability and dose uniformity. Aerosol studies can also assess delivered dose, aerodynamic particle-size distribution and performance under the proposed conditions of use.
Stability and packaging studies may cover assay, degradation products, physical stability and container-closure compatibility. These requirements are product-specific: the characteristics of the marketed formulation should not automatically be assumed to apply to every ensifentrine API source or formulation design.
API Sourcing Considerations for Pharmaceutical Development
Pharmaceutical teams evaluating ensifentrine should distinguish information about the approved medicine from documentation for a particular API. A marketed product does not replace supplier qualification or material-specific analytical evidence.
Relevant sourcing questions include the API specification, batch-specific analytical data, impurity information, manufacturing traceability, storage requirements and documentation appropriate to the intended project. Patent status and regulatory requirements should also be assessed for the proposed use and target market.
TJCY’s approach to pharmaceutical API and excipient sourcing includes attention to supplier qualification, documentation and supply consistency.
Ensifentrine illustrates how a differentiated mechanism and inhalation delivery can create opportunities in respiratory drug development. For questions about respiratory API sourcing, product documentation or current availability, contact TJCY to discuss your project requirements.
